SHR-9839
Phase 2Small molecule
Suzhou Suncadia Biopharmaceuticals Co., Ltd.SHR-9839 is one of 121 small molecule programs targeting Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. It is currently in Phase 2.
4
Indications
5
Total Trials
5
Active Trials
120
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
249 competitors in Patients With Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Avastin
RochePhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Imfinzi
AstraZenecaPhase 2
Halaven
EisaiPhase 2
Kisqali
NovartisPhase 2
Lazcluze
Johnson & JohnsonPhase 2
Adriamycin
PfizerPhase 2
Cyramza
Eli LillyPhase 2
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Ensacove
XXcovery Holdings, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Patients With Advanced Solid Tumors2 trials
Solid Tumors1 trial
NSCLC1 trial
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHR-9839. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details